Hims & Hers Health (HIMS) Tops Q2 EPS by 2c, Revenue Misses, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Hims & Hers Health (HIMS) Tops Q2 EPS by 2c, Revenue Misses, Offers Guidance
August 5, 2025 9:32 AM EDT
BTIG analyst David Larsen reiterated a Buy rating and $85.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments " On Monday, AMC, HIMS reported 2Q:25 results. Revenue of $544.8M +73% y/y was behind BTIG / consensus of $560.9M / $552M though adjusted EBITDA of $82.2M was well ahead of BTIG / consensus of $80.4M / $73M. Excluding several increases in costs related to hiring new talent, EBITDA would have been closer to ~$90M. Relative to our model, the... More
August 5, 2025 6:36 AM EDT
Leerink Partners analyst Michael Cherny raised the price target on Hims and Hers (NYSE: HIMS) to $43.00 (from $42.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: HIMS appears to be in somewhat of a transitory stage, with the companys first revenue miss driven by both the sequential (expected) decline in GLP-1 revenue and the sequential (unexpected) decline in core revenue outside of GLP-1s. We... More
